White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 87, Issue 1, 2010, Pages 117-125

  Yang, Xilin ^a   Ma, Ronald C W ^a   So, Wing Yee ^a   Ko, Gary T C ^a   Kong, Alice P S ^a   Zhao, Hailu ^a   Xu, Gang ^a   Tong, Peter C Y ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ACE inhibitor; Cancer; Type 2 diabetes; White blood cell

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHINESE; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; HONG KONG; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MIDDLE AGED; NEOPLASMS; PATIENT ADMISSION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TRIGLYCERIDES;

EID: 73749083305     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.10.012     Document Type: Article

References (39)

1. Jee S.H., Ohrr H., Sull J.W., Yun J.E., Ji M., and Samet J.M. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293 January (2) (2005) 194-202
2. Seow A., Yuan J.M., Koh W.P., Lee H.P., and Yu M.C. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J. Natl. Cancer Inst. 98 January (2) (2006) 135-138
3. Huxley R., Ansary-Moghaddam A., Berrington de Gonzalez A., Barzi F., and Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 92 June (11) (2005) 2076-2083
4. Rousseau M.C., Parent M.E., Pollak M.N., and Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int. J. Cancer 118 April (8) (2006) 2105-2109
5. Lipscombe L.L., Goodwin P.J., Zinman B., McLaughlin J.R., and Hux J.E. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res. Treat. 98 March (3) (2006) 349-356
6. Friberg E., Orsini N., Mantzoros C.S., and Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50 July (7) (2007) 1365-1374
7. Rodriguez C., Patel A.V., Mondul A.M., Jacobs E.J., Thun M.J., and Calle E.E. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am. J. Epidemiol. 161 January (2) (2005) 147-152
8. Yang X., So W.Y., Ko G.T., Ma R.C., Kong A.P., Chow C.C., et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 179 5 (2008) 427-437
9. Yang X., So W.Y., Ma R.C., Ko G.T., Kong A.P., Wang Q., et al. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr. Relat. Cancer 15 June (2) (2008) 597-607
10. Yoshiji H., Kuriyama S., Noguchi R., Yoshii J., Ikenaka Y., Yanase K., et al. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol. Rep. 15 January (1) (2006) 155-159
11. Yasumatsu R., Nakashima T., Masuda M., Ito A., Kuratomi Y., Nakagawa T., et al. Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J. Cancer Res. Clin. Oncol. 130 October (10) (2004) 567-573
12. Friis S., Sorensen H.T., Mellemkjaer L., McLaughlin J.K., Nielsen G.L., Blot W.J., et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92 November (9) (2001) 2462-2470
13. Sjoberg T., Garcia Rodriguez L.A., and Lindblad M. Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clin. Gastroenterol. Hepatol. 5 October (10) (2007) 1160-6 e1
14. Godsel L.M., Leon J.S., and Engman D.M. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis. Curr. Pharm. Des. 9 9 (2003) 723-735
15. Gage J.R., Fonarow G., Hamilton M., Widawski M., Martinez-Maza O., and Vredevoe D.L. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation 11 3 (2004) 173-180
16. Finn O.J. Cancer immunology. N. Engl. J. Med. 358 June (25) (2008) 2704-2715
17. Shankar A., Wang J.J., Rochtchina E., Yu M.C., Kefford R., and Mitchell P. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch. Intern. Med. 166 January (2) (2006) 188-194
18. Erlinger T.P., Muntner P., and Helzlsouer K.J. WBC count and the risk of cancer mortality in a national sample of U.S. adults: results from the Second National Health and Nutrition Examination Survey mortality study. Cancer Epidemiol. Biomarkers Prev. 13 June (6) (2004) 1052-1056
19. Piwernetz K., Home P.D., Snorgaard O., Antsiferov M., Staehr-Johansen K., and Krans M. For the DiabCare Monitoring Group of the St. Vincent Declaration Steering Committee. Monitoring the targets of the St. Vincent declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabetic Med. 10 (1993) 371-377
20. Information Services Department of Hong Kong, Hong Kong: the Facts. Public Health, Available at: http://wwwinfogovhk/hkfacts/pubhealth-epdf Accessed on 19 May 2006. 2005 October.
21. Yang X.L., So W.Y., Kong A.P., Clarke P., Ho C.S., Lam C.W., et al. End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia 49 October (10) (2006) 2299-2308
22. Ma Y.C., Zuo L., Chen J.H., Luo Q., Yu X.Q., Li Y., et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J. Am. Soc. Nephrol. 17 October (10) (2006) 2937-2944
23. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 June (6) (1972) 499-502
24. Harrell F. Regression Modelling Strategies with applications to Linear Models, Logistic Regression, and Survival Analysis (2001), Spinger-Varlag New York, Inc., New York
25. Durrleman S., and Simon R. Flexible regression models with cubic splines. Stat. Med. 8 May (5) (1989) 551-561
26. Ahlbom A., and Alfredsson L. Interaction: a word with two meanings creates confusion. Eur. J. Epidemiol. 20 7 (2005) 563-564
27. Andersson T., Alfredsson L., Kallberg H., Zdravkovic S., and Ahlbom A. Calculating measures of biological interaction. Eur. J. Epidemiol. 20 7 (2005) 575-579
28. Kalilani L., and Atashili J. Measuring additive interaction using odds ratios. Epidemiol. Perspect. Innov. 3 (2006) 5
29. Li R., and Chambless L. Test for additive interaction in proportional hazards models. Ann. Epidemiol. 17 March (3) (2007) 227-236
30. Yang X., So W.Y., Ma R.C., Ko G.T., Kong A.P., Zhao H., et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 32 October (10) (2009) 1826-1832
31. Joffe M.M., and Rosenbaum P.R. Invited commentary: propensity scores. Am. J. Epidemiol. 150 August (4) (1999) 327-333
32. Rassi Jr. A., Rassi A., Little W.C., Xavier S.S., Rassi S.G., Rassi A.G., et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N. Engl. J. Med. 355 August (8) (2006) 799-808
33. Coleman C.I., Baker W.L., Kluger J., and White C.M. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J. Hypertens. 26 April (4) (2008) 622-629
34. van der Knaap R., Siemes C., Coebergh J.W., van Duijn C.M., Hofman A., and Stricker B.H. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 112 February (4) (2008) 748-757
35. Christian J.B., Lapane K.L., Hume A.L., Eaton C.B., and Weinstock M.A. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J. Natl. Cancer Inst. 100 September (17) (2008) 1223-1232
36. The ADVANCE Collaborative Group. Intensive Blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358 June (24) (2008) 2560-2572
37. Olivares-Reyes J.A., Arellano-Plancarte A., and Castillo-Hernandez J.R. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol. Cell Endocrinol. 302 April (2) (2009) 128-139
38. Liguori A., Abete P., Hayden J.M., Cacciatore F., Rengo F., Ambrosio G., et al. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur. Heart J. 22 November (22) (2001) 2075-2084
39. Yang X., Zhao H., Sui Y., Ma R.C., So W.Y., Ko G.T., et al. Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 58 April (7) (2009) 1518-1525